| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/03/2008 | DE102006047155A1 Cosmetic or dermatological composition comprises 2-isopropyl-5-methylcyclohexylcarbonyl-D-alanine ethyl ester and an antioxidant |
| 04/03/2008 | DE102006047154A1 Cosmetic or dermatological composition comprises 2-isopropyl-5-methylcyclohexylcarbonyl-D-alanine ethyl ester and an antiinflammatory agent |
| 04/03/2008 | DE102006047153A1 Cosmetic or dermatological composition comprises 2-isopropyl-5-methylcyclohexylcarbonyl-D-alanine methyl ester and an antiinflammatory agent |
| 04/03/2008 | DE102006045764A1 Verwendung von Theogallin zur Herstellung eines Arzneimittels zur Prophylaxe und Behandlung von neurologischen und psychiatrischen Erkrankungen des zentralen Nervensystems, insbesondere von mentalen Konzentrationsleistungsstörungen, Depression und Demenz Using theogallin for producing a medicament for the prophylaxis and treatment of neurological and psychiatric diseases of the central nervous system, in particular of mental concentration performance disorders, depression and dementia |
| 04/03/2008 | DE102006044472A1 Geldanamycin-Derivate Geldanamycin derivatives |
| 04/03/2008 | DE102004011720B4 Radiohalogenierte Benzamidderivate und deren Verwendung in der Tumordiagnostik und Tumortherapie Radio Halogenated benzamide derivatives and their use in tumor diagnosis and tumor therapy |
| 04/03/2008 | CA2847852A1 Inhibitors of bruton's tyrosine kinase |
| 04/03/2008 | CA2774197A1 Drugs and uses to modulate inflammation, metabolic disorders and other conditions |
| 04/03/2008 | CA2770486A1 Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| 04/03/2008 | CA2762911A1 Method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, a soluble formulation of a pentacyclic or tetracyclic terpenoid and a pharmaceutical composition containing this soluble formulation |
| 04/03/2008 | CA2700431A1 Nutrient sensor |
| 04/03/2008 | CA2669727A1 Alcohol free formulation of argatroban |
| 04/03/2008 | CA2667756A1 Blocking of gene expression in eukaryotic cells |
| 04/03/2008 | CA2665908A1 New derivatives of 5-thioxilopyranose |
| 04/03/2008 | CA2665907A1 Derivatives of 5-thioxylopyranose and use of same for treatment |
| 04/03/2008 | CA2665339A1 Dispiro tetraoxane compounds |
| 04/03/2008 | CA2664944A1 Use of glycerophospholipids for joint lubrication |
| 04/03/2008 | CA2664935A1 Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c |
| 04/03/2008 | CA2664930A1 Novel 5,7-disubstituted[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-amine derivatives and their use in therapy |
| 04/03/2008 | CA2664847A1 Novel minor groove binders |
| 04/03/2008 | CA2664789A1 5,7-disubstituted[1,3]thiazolo[4,5-d]pyrimidin-2(3h)-one derivatives for the selective inhibtion of chemokine receptors |
| 04/03/2008 | CA2664773A1 Solubilized non-steroidal anti-inflammatory drugs |
| 04/03/2008 | CA2664763A1 Prostaglandin e2 (pge2) as an adjuvant in monoclonal antibody generation |
| 04/03/2008 | CA2664740A1 Combination treatment of cd38-expressing tumors |
| 04/03/2008 | CA2664650A1 Dextran functionalized with hydrophobic amino acids |
| 04/03/2008 | CA2664588A1 Enantiomeric fused-pyridinone compounds with antibacterial activity |
| 04/03/2008 | CA2664572A1 Substituted piperidinophenyl oxazolidinones |
| 04/03/2008 | CA2664568A1 Formulations comprising cyclic compounds |
| 04/03/2008 | CA2664455A1 Pharmaceutical compositions of aripiprazole |
| 04/03/2008 | CA2664420A1 Effervescent ibuprofen formulation with high dissolution rate and process for its preparation |
| 04/03/2008 | CA2664376A1 Polycyclic agents for the treatment of respiratory syncytial virus infections |
| 04/03/2008 | CA2664375A1 Pyrazolo [1, 5-a] pyrimidine derivatives and their therapeutic use |
| 04/03/2008 | CA2664365A1 Soluble epoxide hydrolase inhibitors |
| 04/03/2008 | CA2664364A1 Soluble epoxide hydrolase inhibitors |
| 04/03/2008 | CA2664358A1 Diarylketimine derivative |
| 04/03/2008 | CA2664345A1 Oxepin derivative |
| 04/03/2008 | CA2664342A1 New chemical inhibitors of bacterial heptose synthesis, methods for their preparation and biological applications of said inhibitors |
| 04/03/2008 | CA2664310A1 Compounds which modulate the cb2 receptor |
| 04/03/2008 | CA2664301A1 Fused ring compounds for inflammation and immune-related uses |
| 04/03/2008 | CA2664296A1 Novel inhibitors of beta-lactamase |
| 04/03/2008 | CA2664290A1 Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| 04/03/2008 | CA2664268A1 Diaryl oxadiazol derivatives |
| 04/03/2008 | CA2664258A1 [2-(6-flouro-1h-indol-3-ylsulfanyl)benzyl]methyl amine for the treatment of affective disorders |
| 04/03/2008 | CA2664245A1 Acylated piperidine derivatives as melanocortin-4 receptor modulators |
| 04/03/2008 | CA2664156A1 Compositions of tlr ligands and antivirals |
| 04/03/2008 | CA2664124A1 New class of terpene-derived compounds having an antibiotic activity, compositions containing the same ans uses thereof |
| 04/03/2008 | CA2664120A1 Pyridooxazepine progesteron receptor modulators |
| 04/03/2008 | CA2664113A1 Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer |
| 04/03/2008 | CA2664052A1 An improved process for the preparation of temozolomide and analogs |
| 04/03/2008 | CA2664037A1 Sulfonamide derivatives |
| 04/03/2008 | CA2664031A1 Quinoline derivatives with 5-ht-binding properties |
| 04/03/2008 | CA2663731A1 5-substituted quinazolinone derivatives and compositions comprising and methods of using the same |
| 04/03/2008 | CA2663574A1 Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid |
| 04/03/2008 | CA2663569A1 Pharmaceutical compositions of hdac inhibitors and chelatable metal compounds, and metal-hdac inhibitor chelate complexes |
| 04/03/2008 | CA2663116A1 Inhibitors of bruton's tyrosine kinase |
| 04/03/2008 | CA2663080A1 Derivatives of pyrrolizine, indolizine and quinolizine, preparation thereof and therapeutic use thereof |
| 04/03/2008 | CA2663026A1 Apoptotic cell-mediated transfection of mammalian cells with interfering rna |
| 04/03/2008 | CA2662992A1 2-methylene-(20r,25s)-19,27-dinor-(22e)-vitamin d analogs |
| 04/03/2008 | CA2662864A1 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs |
| 04/03/2008 | CA2662612A1 3-aza-bicyclo[3.1.0]hexane derivatives |
| 04/03/2008 | CA2662571A1 Pharmaceutical compositions |
| 04/03/2008 | CA2662383A1 Organic compounds |
| 04/03/2008 | CA2662309A1 Crystalline forms of valrubicin and processes for their preparation |
| 04/03/2008 | CA2661576A1 Stabilizing compositions for antibiotics and methods of use |
| 04/03/2008 | CA2660377A1 Quinolinone derivatives |
| 04/02/2008 | EP1905845A2 Method for detecting multiple myeloma and method for inhibiting the same |
| 04/02/2008 | EP1905831A2 Lactoferrin receptor genes of moraxella |
| 04/02/2008 | EP1905830A1 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 04/02/2008 | EP1905780A1 Cancer suppressing agent |
| 04/02/2008 | EP1905778A2 Novel 2'-C-methyl nucleoside derivatives |
| 04/02/2008 | EP1905775A1 Tetracyclic compounds, method of preparing them, pharmaceutical compositions containing them and their use as dopamine receptors ligands |
| 04/02/2008 | EP1905774A1 Fused heterocyclic compounds as serotonin receptor modulators |
| 04/02/2008 | EP1905773A2 Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase |
| 04/02/2008 | EP1905771A2 Quinuclidine derivatives and their use |
| 04/02/2008 | EP1905769A1 Heterocycle-substituted benzimidazole derivative |
| 04/02/2008 | EP1905766A1 Glycolipid derivative and therapeutic agent comprising the same as active ingredient |
| 04/02/2008 | EP1905765A1 6-arylamino-5-cyano-4-pyrimidinone as PDE9A-inhibitors |
| 04/02/2008 | EP1905764A1 Substituted 2-Phenyl-benzimidazoles and their use as pharmaceuticals |
| 04/02/2008 | EP1905763A1 N-acylic aminoacid derivatives. method for the production thereof, pharmacological composition and the use in the form of anti-allergic, anti-inflammatory and hypolipidemic agents |
| 04/02/2008 | EP1905762A1 Pyrazolone derivative |
| 04/02/2008 | EP1905759A1 N-[1-(3-amino-4-phenyl-butyryl)-4-hydroxy-pyrrolidin-2-ylmethyl}-propionamide and related compounds as dpp-iv inhibitors for the treatment oftype 2 diabetes mellitus |
| 04/02/2008 | EP1905757A1 Derivatives of Venlafaxine and methods of preparing and using the same |
| 04/02/2008 | EP1905457A1 Angiogenesis and vascular permeability modulators and inhibitors |
| 04/02/2008 | EP1905456A1 Drug-containing photocrosslinked hyaluronic acid derivative gel |
| 04/02/2008 | EP1905454A1 Formulations comprising cyclic compounds |
| 04/02/2008 | EP1905452A1 Agent for prevention or treatment of glaucoma |
| 04/02/2008 | EP1905451A1 Combinations comprising antimuscarinic agents and corticosteroids |
| 04/02/2008 | EP1905450A1 Pharmaceutical composition containing ppar gamma agonist |
| 04/02/2008 | EP1905449A2 Vaccines |
| 04/02/2008 | EP1905446A1 Use of PYY analogs and antagonists of PPY receptors for manipulating satiety |
| 04/02/2008 | EP1905444A1 Medicinal composition containing ginseng secondary glycosides, its preparation method and application |
| 04/02/2008 | EP1905443A1 Liquid for preventing tissue adhesion and method of preventing tissue adhesion |
| 04/02/2008 | EP1905442A1 Utilization of anti-neuropathic pain effect of d-allose and d-psicose |
| 04/02/2008 | EP1905441A2 Non-sedating barbiturate compounds as neuroprotective agents |
| 04/02/2008 | EP1905440A1 Use of a pharmaceutical composition comprising an anticholinergic for killing microorganisms and for treating respiratory tract infections |
| 04/02/2008 | EP1905439A1 Second line treatment of metastatic hormone refractory prostate cancer using satraplatin |
| 04/02/2008 | EP1905438A2 Hypoglycemic agent |
| 04/02/2008 | EP1905437A1 Treatment of pain using satraplatin |
| 04/02/2008 | EP1905436A1 Synergistic time-delaying agent for local anestheic |
| 04/02/2008 | EP1905435A2 Titration dosing regimen for controlled release tramadol |